PMID- 26926145
OWN - NLM
STAT- MEDLINE
DCOM- 20160726
LR  - 20190222
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 2
DP  - 2016
TI  - Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) 
      Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.
PG  - e0149460
LID - 10.1371/journal.pone.0149460 [doi]
LID - e0149460
AB  - Epidemic methicillin-resistant Staphylococcus aureus (MRSA) imposes an increasing 
      impact on public health. Due to multi-antibiotics resistance in MRSA strains, 
      there is an urgent need to develop novel therapeutics such as effective 
      monoclonal antibodies (mAbs) against MRSA infections. Staphylococcus aureus 
      surface protein A (SasA), a large surface-located protein (~240 kDa), is one of 
      MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) and 
      a potential target for immunotherapeutic approaches against S. aureus infections. 
      In the present study, we analyzed the sequence of SasA with bioinformatics tools 
      and generated a protective monoclonal antibody (2H7) targeting the conserved 
      domain of SasA. 2H7 was shown to recognize wild-type S. aureus and promote 
      opsonophagocytic killing of S. aureus. In both sepsis and peritoneal infection 
      models, prophylactic administration of 2H7 improved the survival of BALB/c mice 
      challenged by S. aureus strain USA300 and ST239 (prevalent MRSA clones in North 
      America and Asian countries, respectively) and enhanced bacterial clearance in 
      kidneys. Additionally, 2H7 prophylaxis prevented the formation of intraperitoneal 
      abscess in a murine model of peritoneal infection and therapeutic administration 
      of 2H7 showed protective efficacy in a murine sepsis model. Our results presented 
      here provide supporting evidences that an anti-SasA mAb might be a potential 
      component in an antibody-based immunotherapeutic treatment of MRSA infections.
FAU - Yang, Yilong
AU  - Yang Y
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Qian, Mengying
AU  - Qian M
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Yi, Shaoqiong
AU  - Yi S
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Liu, Shuling
AU  - Liu S
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Li, Bing
AU  - Li B
AD  - Department of Clinical Laboratory, 306 Hospital of People's Liberation Army, 
      Beijing, PR China.
FAU - Yu, Rui
AU  - Yu R
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Guo, Qiang
AU  - Guo Q
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Zhang, Xiaopeng
AU  - Zhang X
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Yu, Changming
AU  - Yu C
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Li, Jianmin
AU  - Li J
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Xu, Junjie
AU  - Xu J
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
FAU - Chen, Wei
AU  - Chen W
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160229
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Bacterial Proteins)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Antibodies, Monoclonal/immunology/*pharmacology
MH  - Bacterial Proteins/*antagonists & inhibitors/genetics/immunology/metabolism
MH  - Blood Platelets/metabolism
MH  - Disease Models, Animal
MH  - Female
MH  - Methicillin-Resistant Staphylococcus aureus/drug effects/immunology
MH  - Mice
MH  - Peritonitis/drug therapy/*microbiology
MH  - Phagocytosis/drug effects/immunology
MH  - Protein Binding
MH  - Sepsis/drug therapy/*microbiology
MH  - Sequence Analysis, DNA
MH  - Staphylococcal Infections/drug therapy/*microbiology/mortality
MH  - Staphylococcus aureus/*drug effects/genetics/immunology
PMC - PMC4771200
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/03/02 06:00
MHDA- 2016/07/28 06:00
PMCR- 2016/02/29
CRDT- 2016/03/02 06:00
PHST- 2015/12/11 00:00 [received]
PHST- 2016/02/01 00:00 [accepted]
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
PHST- 2016/02/29 00:00 [pmc-release]
AID - PONE-D-15-52013 [pii]
AID - 10.1371/journal.pone.0149460 [doi]
PST - epublish
SO  - PLoS One. 2016 Feb 29;11(2):e0149460. doi: 10.1371/journal.pone.0149460. 
      eCollection 2016.